Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Qingcheng Guo"'
Publikováno v:
Journal of Materials Research and Technology, Vol 30, Iss , Pp 7352-7363 (2024)
In this study, 304 antimicrobial stainless steel coatings were prepared by the electron beam melting of antimicrobial stainless steel powder, in an attempt to enhance the surface properties of Q345R steel. Besides, the effect of Cu-containing 304 pow
Externí odkaz:
https://doaj.org/article/12edfdeb2857472198f61dea22f40821
Autor:
Xuekun Wang, Jin Xu, Qingcheng Guo, Zhenhua Li, Jiawei Cao, Rongrong Fu, Mengjiao Xu, Xiang Zhao, Fugui Wang, Xinmeng Zhang, Taimin Dong, Xu Li, Weizhu Qian, Shen Hou, Lusha Ji, Dapeng Zhang, Huaizu Guo
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 12 (2024)
The Chinese hamster ovarian (CHO) cells serve as a common choice in biopharmaceutical production, traditionally cultivated in stirred tank bioreactors (STRs). Nevertheless, the pursuit of improved protein quality and production output for commercial
Externí odkaz:
https://doaj.org/article/f622f91f8c874caca261685bcf9c9c2e
Autor:
Yichen Zhang, Yiming Xiao, Qingcheng Guo, Feng Cui, Jiaxin Zhao, Guangping Wu, Chaofeng Wu, Wu Liu
Publikováno v:
Biomimetics, Vol 9, Iss 8, p 449 (2024)
This study aimed to enhance the stability and response speed of a passive stabilized double-wing flapping micro air vehicle (FMAV) by implementing a feedback-controlled biomimetic tail. A model for flapping wings accurately calculated the lift force
Externí odkaz:
https://doaj.org/article/7e6719e45e2e46c6abef0da356417f54
Autor:
Tao Liu, Jin Xu, Qingcheng Guo, Dapeng Zhang, Jun Li, Weizhu Qian, Huaizu Guo, Xinli Zhou, Sheng Hou
Publikováno v:
Frontiers in Chemistry, Vol 10 (2022)
Succinimide (Asu) is the intermediate for asparagine deamidation in therapeutic proteins, and it can be readily hydrolyzed to form aspartate and iso-aspartate residues. Moreover, Asu plays an important role in the protein degradation pathways, aspara
Externí odkaz:
https://doaj.org/article/5f3ee0b26b2d4cf3afdf3973c00ae3e3
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Objective: Pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity studies were conducted to evaluate the bioequivalence of CMAB807, a biosimilar to denosumab (Prolia®), which is the only approved RANKL inhibitor for the treatment of
Externí odkaz:
https://doaj.org/article/a3ce38e4720a48a08ddfb85b5bc8707a
Publikováno v:
Applied Sciences, Vol 12, Iss 18, p 9104 (2022)
With the complex aerodynamics, the accurate system model of the flapping-wing micro aerial vehicle required for precise control is hard to acquire, meanwhile, due to the unique control strategy, the coupling between the actuators also brings a great
Externí odkaz:
https://doaj.org/article/57df3f8ba3aa492486b0a06220109b58
In order to achieve improved tracking performance, this paper considers the distinct features of tailless flapping wing micro air vehicles (FWMAVs), and proposes a robust $\bm{H_{\infty}}$ controller. A linear parameter Varying (LPV) model is establi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::678462a177741d9b0ccc07ef8673ab75
https://doi.org/10.36227/techrxiv.21184678
https://doi.org/10.36227/techrxiv.21184678
To overcome the aerodynamic and system parameters uncertainties of the tailless flapping wing micro aerial vehicle (FWMAV) caused by inaccurate measurement, we establish an linear parameter varying (LPV) model and propose a H∞ controller with the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a04fa28491e8e47ec1a7db7cbf154b72
https://doi.org/10.36227/techrxiv.21184678.v2
https://doi.org/10.36227/techrxiv.21184678.v2
Robust control is essential to the flapping wing micro aerial vehicle (FWMAV) due to model uncertainties, environmental or self changes during flight, such as the change of drag coefficient caused by airflow and the asymmetric effect caused by wing d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::652f276cf7a04f158e24190d2db72325
https://doi.org/10.36227/techrxiv.21184678.v1
https://doi.org/10.36227/techrxiv.21184678.v1
Autor:
Tao Liu, Yantao Li, Jin Xu, Qingcheng Guo, Lei Zhu, Tuo Fu, Jun Li, Dapeng Zhang, Weizhu Qian, Xinli Zhou, Huaizu Guo, Sheng Hou
Publikováno v:
Journal of pharmaceutical and biomedical analysis. 220
The early intervention is essential, and later development cannot compensate for this initial generation of an antibody drug. Especially for sequence variants (SVs), should cause concern during the early bioprocess development. The advancement of bio